Significance of Evaluating Tumor Markers in the Oncological Criteria for Resectability in Hepatocellular Carcinoma
- 17 December 2025
- journal article
- Published by Wiley in Hepatology Research
- Vol. 56 (4) , 550-561
Abstract
Background: The Japan Liver Cancer Association and the Japanese Society of Hepato‐Biliary‐Pancreatic Surgery proposed oncological resectability criteria for hepatocellular carcinoma (HCC), classifying tumors as R, BR1, or BR2. However, serum tumor markers, such as alpha‐fetoprotein (AFP) and des‐gamma‐carboxyprothrombin (DCP), despite their prognostic value, were not incorporated. Methods: We retrospectively analyzed 803 patients undergoing curative liver resection for HCC. Significant tumor marker elevation (TM‐high) was defined as AFP > 500 ng/mL or DCP > 1000 mAU/mL. Overall survival (OS) and relapse‐free survival (RFS) were compared according to resectability status and tumor marker levels. Results: TM‐high status was observed in 171 patients with R (32.3%), 75 patients with BR1 (27.5%), and 46 patients with BR2 (70.1%). In the R group, TM‐high patients had significantly worse outcomes than non‐TM‐high patients (median survival time [MST], RFS: 26.9 vs. 55.9 months, and p < 0.001; OS: 120.7 vs. 160.8 months and p = 0.008). No significant difference in the OS was observed between R/TM‐high and BR1/non–TM‐high patients (120.7 vs. 103.1 months and p = 0.159) or BR1/TM‐high and BR2/non–TM‐high patients (58.7 vs. 58.5 months and p = 0.657). Multivariate analyses confirmed that a TM‐high status was an independent predictor for both the RFS (HR 1.36 and p < 0.003) and OS (HR 1.50 and p < 0.001). Conclusion: AFP and DCP provide independent prognostic information beyond the oncological resectability criteria. Incorporating tumor markers may refine risk stratification and optimize multidisciplinary treatment strategies for HCC.Keywords
This publication has 22 references indexed in Scilit:
- Prognostic factors and clinical significance of preoperative systemic therapy in patients with borderline resectable hepatocellular carcinoma: A JSHBPS project study 2023, Part 2Journal of Hepato-Biliary-Pancreatic Sciences, 2025
- Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 studyThe Lancet, 2025
- Enhancing HCC recurrence prediction after liver transplantation: From DCP plus AFP-L3 model to GALAD scoreJournal of Hepatology, 2023
- AFP-L3 and DCP strongly predict early hepatocellular carcinoma recurrence after liver transplantationJournal of Hepatology, 2023
- BCLC strategy for prognosis prediction and treatment recommendation: The 2022 updateJournal of Hepatology, 2021
- Prognostic value of expanded liver transplantation criteria—the 5‐5‐500 rule—in patients with hepatic resection for intermediate‐stage hepatocellular carcinomaJournal of Hepato-Biliary-Pancreatic Sciences, 2020
- Atezolizumab plus Bevacizumab in Unresectable Hepatocellular CarcinomaNew England Journal of Medicine, 2020
- Prevention of recurrence after resection of hepatocellular carcinoma: A daunting challengeHepatology, 2011
- PIVKA-II is a candidate marker for monitoring the effects of the oral anticoagulant warfarinClinical Biochemistry, 2010
- Sorafenib in Advanced Hepatocellular CarcinomaNew England Journal of Medicine, 2008